Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma

T Grönroos, L Bentzen, P Marjamäki, R Murata… - European Journal of …, 2004 - Springer
The first aim of this study was to compare the hypoxia imaging ability of fluorine-18
fluoroerythronitroimidazole ([ 18 F]FETNIM) with that of fluorine-18 fluoromisonimidazole ([ 18 F]…

[HTML][HTML] Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size

F Baba, Y Shibamoto, H Ogino, R Murata, C Sugie… - Radiation …, 2010 - Springer
Background The treatment schedules for stereotactic body radiotherapy (SBRT) for lung
cancer vary from institution to institution. Several reports have indicated that stage IB patients …

An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma

R Murata, Y Nishimura, M Hiraoka - International Journal of Radiation …, 1997 - elibrary.ru
Purpose: TNP-470, a synthetic analogue of fumagillin which is a natural product of Aspergillus
fumigatus, has been noted as an angiogenesis inhibitor. Combined effects of TNP-470 …

Differences in target outline delineation from CT scans of brain tumours using different methods and different observers

…, Y Nagata, K Okajima, T Ishigaki, R Murata… - Radiotherapy and …, 1999 - Elsevier
Purpose: To assess errors resulting from manual transfer of contour information for three-dimensional
(3-D) target reconstruction, and to determine variations in target volume …

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

R Murata, DW Siemann, J Overgaard… - Radiotherapy and …, 2001 - Elsevier
Background and purpose: The ability of combretastatin A-4 disodium phosphate (CA4DP) to
induce vascular damage and enhance the radiation response of murine tumors was …

Improved tumor response by combining radiation and the vascular-damaging drug 5, 6-dimethylxanthenone-4-acetic acid

R Murata, DW Siemann, J Overgaard… - Radiation …, 2001 - meridian.allenpress.com
Murata, R., Siemann, DW, Overgaard, J. and Horsman, MR Improved Tumor Response by
Combining Radiation and the Vascular-Damaging Drug 5,6-Dimethylxanthenone-4-acetic …

Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor

S Otsuka, Y Shibamoto, H Iwata, R Murata… - International Journal of …, 2011 - Elsevier
PURPOSE: To evaluate the compliance of linear-quadratic (LQ) model calculations in the
high-dose range as used in stereotactic irradiation in a murine tumor model. METHODS AND …

Pancreatic cavernous hemangioma: CT, MRI, US, and angiography characteristics

H Kobayashi, T Itoh, R Murata, M Tanabe - Gastrointestinal radiology, 1991 - Springer
A large pancreatic cavernous hemangioma was found in a 30-year-old man with abdominal
distention. Plain and contrast-enhanced computed tomography (CT), magnetic resonance …

[HTML][HTML] Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical mode

T Murai, Y Shibamoto, Y Manabe, R Murata, C Sugie… - Radiation …, 2013 - Springer
Purpose With the new mode of Tomotherapy, irradiation can be delivered using static ports
of the TomoDirect mode. The purpose of this study was to evaluate the characteristics of …

Combination of vascular targeting agents with thermal or radiation therapy

MR Horsman, R Murata - … Journal of Radiation Oncology* Biology* Physics, 2002 - Elsevier
Purpose : The most likely clinical application of vascular targeting agents (VTAs) is in
combination with more conventional therapies. In this study, we report on preclinical studies in …